false
0001624326
0001624326
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 13, 2026
PAVMED INC.
(Exact
Name of Registrant as Specified in Charter)
| Delaware |
|
001-37685 |
|
47-1214177 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
| 360
Madison Avenue, 25th Floor, New York, New York |
|
10017 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (917) 813-1828
| N/A |
| (Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, Par Value $0.001 Per Share |
|
PAVM |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On
November 13, 2026, PAVmed Inc. (the “Company”) issued a press release announcing financial results for its fiscal
quarter ended September 30, 2026 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1
and is incorporated herein by reference.
Item
7.01. Regulation FD Disclosure.
The
disclosure set forth under Item 2.02 is incorporated herein by reference.
The
information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of
the Company, except as shall be expressly set forth by specific reference in such document.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits:
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press release. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Dated:
November 13, 2026 |
PAVMED
INC. |
| |
|
| |
By:
|
/s/
Dennis McGrath |
| |
|
Dennis
McGrath |
| |
|
President
and Chief Financial Officer |
Exhibit
99.1
PAVmed
Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
Lucid
Diagnostics’ EsoGuard® now fully reimbursed by Medicare nationwide
Veris
Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission
PAVmed engaged with FDA on PortIO and Octeris
Conference
call and webcast to be held today, November 13, at 8:30 AM EST
NEW
YORK, November 13, 2026 - PAVmed Inc. (NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage
medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update
for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”), Veris Health Inc. (“Veris”),
and Octeris Medical Inc. (“Octeris”), and reported financial results for the third quarter ended September 30, 2026.
Conference
Call and Webcast
The
webcast will take place on Friday, November 13, 2026, at 8:30 AM EST and is accessible in the investor relations section of the Company’s
website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184
and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “PAVmed
Business Update” to join.
Following
the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s
website at pavmed.com.
Business
Update Highlights
“We’re
very encouraged by developments across the PAVmed portfolio,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief
Executive Officer. “Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid’s
largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity. Veris continues
to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with
FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value.”
Highlights
from the third quarter and recent weeks:
| ◌ | Began
receiving payments from Medicare for the EsoGuard® Esophageal DNA
Test in October. Lucid is submitting Medicare claims for tests performed at its Texas laboratory
to Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over that laboratory,
and is receiving payments at EsoGuard’s established Clinical Laboratory Fee Schedule
rate. |
| ◌ | Focused
commercial efforts on expanding EsoGuard access among at-risk Medicare beneficiaries, who
represent approximately 50% of the 30 million patients recommended for esophageal precancer
testing by professional society guidelines. |
| ◌ | Announced
publication of an 11,991-patient real-world EsoGuard study in the peer-reviewed journal
Diagnostics, the largest peer-reviewed study of nonendoscopic esophageal precancer
testing to date, demonstrating the efficiency and scalability of the EsoCheck®
Esophageal Cell Collection Device. |
| ◌ | Performed
2,871 EsoGuard tests and recognized revenue of $1.2 million in 3Q26. October was a record
month for EsoGuard test volume, with more than 1,800 tests. |
| ◌ | Monthly
patient enrollment at OSU-The James grew throughout the quarter, nearly doubling from July
to September, as the commercial phase of the strategic engagement continued to accelerate
and the clinical rollout went live across most departments. |
| ◌ | Achieved
design freeze for the implantable physiological monitor and, in October, initiated the 90-day
GLP animal study, keeping the device on track for an early 2027 FDA 510(k) submission. |
| ◌ | Held
an initial meeting with FDA on PortIO in late October, to be followed by an in-person pre-submission
meeting in January 2027 focused on the device’s regulatory pathway. |
| ● | Octeris: |
| | |
| ◌ | Completed
Octeris’ next-generation multimodal endoscopic imaging probe, which is ready for clinical
testing. Octeris expects to submit its initial FDA pre-submission package this month, with
enrollment in the University of North Carolina clinical validation study expected to begin
in January 2027. |
Preliminary Financial
Results:
| ● | For
the three months ended September 30, 2026, operating expenses were approximately $6.8 million,
which included stock-based compensation expenses of $1.0 million. |
| ● | As
shown below and for the purpose of illustrating the effect of stock-based compensation and
other non-cash income and expenses on the Company’s financial results, the Company’s
non-GAAP adjusted net loss was approximately $1.2 million or $(0.19) per common share. |
| ● | PAVmed
had cash and cash equivalents of $8.9 million, including restricted cash of $5.3 million,
as of September 30, 2026, compared to cash and cash equivalents of $1.5 million, including
$0.3 million of restricted cash, as of December 31, 2025. |
PAVmed
Non-GAAP Measures
| ● | To
supplement our financial results presented in accordance with U.S. generally accepted accounting
principles (GAAP), management provides certain non-GAAP financial measures of the Company’s
financial results. These non-GAAP financial measures include net loss before interest, taxes,
depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts
EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible
securities, the periodic change in fair value of convertible securities, and loss on debt
extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted
loss are not recognized terms under U.S. GAAP. |
| ● | Non-GAAP
financial measures are presented with the intent of providing greater transparency to the
information used by us in our financial performance analysis and operational decision-making.
We believe these non-GAAP financial measures provide meaningful information to assist investors,
shareholders, and other readers of our financial statements in making comparisons to our
historical financial results and analyzing the underlying performance of our results of operations.
These non-GAAP financial measures are not intended to be, and should not be, a substitute
for, considered superior to, considered separately from, or as an alternative to, the most
directly comparable GAAP financial measures. |
| ● | Non-GAAP
financial measures are provided to enhance readers’ overall understanding of our current
financial results and to provide further information for comparative purposes. Management
believes the non-GAAP financial measures provide useful information to management and investors
by isolating certain expenses, gains, and losses that may not be indicative of our core operating
results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP
adjusted loss, and its presentation is intended to help the reader understand the effect
of the loss on the issuance or modification of convertible securities, the periodic change
in fair value of convertible securities, the loss on debt extinguishment and the corresponding
accounting for non-cash charges on financial performance. In addition, management believes
non-GAAP financial measures enhance the comparability of results against prior periods. |
| ● | A
reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures
included in this press release for the three and nine months ended September 30, 2026 and
2025 are as follows: |
| |
For the three months ended September 30, | |
For the nine months ended September 30, |
| | |
2026 | |
2025 | |
2026 | |
2025 |
| (in thousands except per-share amounts) | |
| |
| |
| |
|
| Revenue | |
$ | 41 | | |
$ | 5 | | |
$ | 96 | | |
$ | 19 | |
| Operating expenses | |
| 6,768 | | |
| 4,849 | | |
| 21,879 | | |
| 15,022 | |
| Other (Income) Expense, net | |
| 6,308 | | |
| 1,167 | | |
| (1,087 | ) | |
| (15,291 | ) |
| Net (Income) Loss | |
| 13,035 | | |
| 6,011 | | |
| 20,696 | | |
| (288 | ) |
| Net income (loss) attributable to common stockholders | |
| (11,752 | ) | |
| (6,328 | ) | |
| (24,219 | ) | |
| (1,942 | ) |
| Preferred Stock dividends and deemed dividends | |
| 97 | | |
| 945 | | |
| 7,120 | | |
| 3,606 | |
| Net income (loss) as reported | |
| (11,655 | ) | |
| (5,383 | ) | |
| (17,099 | ) | |
| 1,664 | |
| Adjustments: | |
| | | |
| | | |
| | | |
| | |
| Depreciation and amortization expense1 | |
| 19 | | |
| 22 | | |
| 58 | | |
| 87 | |
| Interest expense, net2 | |
| (2 | ) | |
| (2 | ) | |
| (26 | ) | |
| (8 | ) |
| NCI ownership share of Interest and Depreciation adjustments | |
| (268 | ) | |
| — | | |
| (775 | ) | |
| — | |
| EBITDA | |
| (11,906 | ) | |
| (5,363 | ) | |
| (17,842 | ) | |
| 1,743 | |
| | |
| | | |
| | | |
| | | |
| | |
| Other non-cash or financing related expenses: | |
| | | |
| | | |
| | | |
| | |
| Stock-based compensation expense3 | |
| 967 | | |
| 383 | | |
| 2,065 | | |
| 1,475 | |
| Operating expenses issued in stock1 | |
| 140 | | |
| 52 | | |
| 2,091 | | |
| 155 | |
| Change in FV equity method investments | |
| 9,985 | | |
| 4,382 | | |
| 10,612 | | |
| (5,979 | ) |
| Preliminary
Change in FV convertible debt2 | |
| (330 | ) | |
| 100 | | |
| (3,126 | ) | |
| 349 | |
| Loss on debt extinguishment2 | |
| — | | |
| — | | |
| 3,422 | | |
| 58 | |
| Change in fair value – warrant liability | |
| — | | |
| — | | |
| (1,831 | ) | |
| — | |
| Change in fair value – rights liability | |
| (96 | ) | |
| — | | |
| (150 | ) | |
| — | |
| Non-GAAP adjusted (loss) | |
$ | (1,240 | ) | |
$ | (446 | ) | |
$ | (4,759 | ) | |
$ | (2,199 | ) |
| Non-GAAP shares outstanding, basic and diluted | |
| 6,640 | | |
| 718 | | |
| 4,849 | | |
| 596 | |
| Non-GAAP adjusted (loss) income per share, basic and diluted | |
$ | (0.19 | ) | |
$ | (0.62 | ) | |
$ | (0.98 | ) | |
$ | (3.69 | ) |
1
Included in general and administrative expenses in the financial statements.
2
Included in other income and expenses.
3
Stock-based compensation (“SBC”) expense is included in operating expenses and is detailed as follows in the table
below by category within operating expenses for the non-GAAP Net operating expenses:
| (in thousands except per-share amounts) | |
For the three months ended
September 30, | |
For the nine months ended September 30, |
| | |
2026 | |
2025 | |
2026 | |
2025 |
| | |
| |
| |
| |
|
| Cost of revenue | |
$ | 158 | | |
$ | 55 | | |
$ | 377 | | |
$ | 133 | |
| Stock-based compensation expense3 | |
| — | | |
| — | | |
| — | | |
| — | |
| Net cost of revenue | |
| 158 | | |
| 55 | | |
| 377 | | |
| 133 | |
| | |
| | | |
| | | |
| | | |
| | |
| Sales and marketing | |
| 206 | | |
| 201 | | |
| 636 | | |
| 668 | |
| Stock-based compensation expense3 | |
| (17 | ) | |
| (13 | ) | |
| (30 | ) | |
| (59 | ) |
| Net sales and marketing | |
| 189 | | |
| 188 | | |
| 606 | | |
| 609 | |
| | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 4,482 | | |
| 3,505 | | |
| 15,489 | | |
| 11,557 | |
| Depreciation expense | |
| (19 | ) | |
| (22 | ) | |
| (58 | ) | |
| (87 | ) |
| Operating expenses issued in stock | |
| (140 | ) | |
| (52 | ) | |
| (2,091 | ) | |
| (155 | ) |
| Stock-based compensation expense3 | |
| (899 | ) | |
| (332 | ) | |
| (1,927 | ) | |
| (1,276 | ) |
| Net general and administrative | |
| 3,424 | | |
| 3,099 | | |
| 11,413 | | |
| 10,039 | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
| 1,922 | | |
| 1,088 | | |
| 5,377 | | |
| 2,664 | |
| Stock-based compensation expense3 | |
| (51 | ) | |
| (38 | ) | |
| (108 | ) | |
| (140 | ) |
| Net research and development | |
| 1,871 | | |
| 1,050 | | |
| 5,269 | | |
| 2,524 | |
| | |
| | | |
| | | |
| | | |
| | |
| Total operating expenses | |
| 6,768 | | |
| 4,849 | | |
| 21,879 | | |
| 15,022 | |
| Depreciation and amortization expense | |
| (19 | ) | |
| (22 | ) | |
| (58 | ) | |
| (87 | ) |
| Operating expenses issued in stock | |
| (140 | ) | |
| (52 | ) | |
| (2,091 | ) | |
| (155 | ) |
| Stock-based compensation expense3 | |
| (967 | ) | |
| (383 | ) | |
| (2,065 | ) | |
| (1,475 | ) |
| Net operating expenses | |
$ | 5,642 | | |
$ | 4,392 | | |
$ | 17,665 | | |
$ | 13,305 | |
About
PAVmed and its Subsidiaries
PAVmed
Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors.
Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets
the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other
subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring
using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently
developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the
Veris Cancer Care Platform.
For
more information about PAVmed, please visit pavmed.com.
For
more information about Lucid Diagnostics, please visit luciddx.com.
For
more information about Veris Health, please visit verishealth.com.
Forward-Looking
Statements
This
press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements
that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s
and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s
and Lucid’s common stock; general economic and market conditions; the uncertainties inherent in research and development, including
the cost and time required to advance PAVmed’s and Lucid’s products to regulatory submission; whether regulatory authorities
will be satisfied with the design of and results from PAVmed’s and Lucid’s clinical and preclinical studies; whether and
when PAVmed’s and Lucid’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and Lucid’s
products once cleared and commercialized; PAVmed’s and Lucid’s ability to raise additional funding as needed; and other competitive
developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and
description of these and other important risks and uncertainties that may affect PAVmed’s and Lucid’s future operations,
see Part I, Item 1A, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report
on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly
update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on
which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the
forward-looking statements.
Investor
and Media Contact
Matt
Riley
Vice
President
PAVmed and Lucid Diagnostics
mjr@pavmed.com